Serum Lipoprotein(a) and Lipid Levels in Patients with Chronic Plaque Type Psoriasis

Abstract

Introduction: Psoriasis vulgaris (PV) was considered to be a chronic, recurrent skin disease, but it has been accepted as a chronic systemic inflammatory disease in recent years. Lipoprotein(a) (Lp(a)) is a lipoprotein that is synthesized in the liver and has a low-density lipoprotein (LDL)-like molecular structure consisting of phospholipids, cholesterol, and apolipoprotein B-100 derivative. Serum levels of Lp(a) are not affected by the amount of lipid incorporated into the diet and lifestyle changes. The aim of this study is to compare blood lipid and Lp(a) levels between the PV patient group and healthy control group and to investigate whether psoriasis creates a predisposition to atherosclerosis. Methods: Forty-four patients with clinical and/or histopathological diagnosis of chronic plaque-type PV and 48 healthy subjects were included in the study. Serum total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, serum LDL cholesterol, very low-density lipoprotein (VLDL) cholesterol, and serum Lp(a) levels were measured. Results: Total cholesterol, triglyceride, and HDL, LDL, and VLDL cholesterol levels were not statistically different between the psoriasis and healthy control groups (p=0.071, p=0.374, p=0.060, p=0.421, and p=0.759, respectively). Lp(a) levels were higher in the psoriasis group than in the healthy control group (p<0.001). Discussion and Conclusion: According to the results of our study, increased Lp(a) levels in patients with psoriasis may be more likely to induce atherosclerosis than those in the normal population. On the other hand, the identification of the Lp(a) level in patients with psoriasis with cardiovascular diseases may be an appropriate diagnostic tool for the evaluation of atherosclerotic and vasoocclusive pathologies.

Role of Interleukin-18, Tumor Necrosis Factor-α, Osteopontin, Paraoxonase and Lipoprotein (a) in Psoriasis Pathogenicity.

“…This study shows that mean serum lipoprotein (a) value was significantly higher in psoriasis as compared to controls. Previous studies from other geographical areas reported elevation of serum LP (a) in psoriasis [57][58][59][60]. Cardiovascular atherosclerotic diseases are common in psoriasis [109][110][111].…”

“…Many studies reported that lipoprotein (a) [LP (a)] was a risk factor for cardiovascular disease development [82]. In literature, 4 case-control studies found significant increase in serum Lp (a) levels in patients with psoriasis and two of them found significant correlation between serum Lp (a) and disease severity [57][58][59][60].…”